Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on JLP-1207 PK in Healthy Volunteers
NCT02447367Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Jul 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of JLP-1207 in benign prostatic hyperplasia (BPH), overactive bladder (OAB) and lower urinary tract symptoms (LUTS) (2 arms), sponsored by Jeil Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Curve from time zero to last measurable concentration at 192 hours, Maximum Plasma Concentration at 192 hours and 1 more. Started Jul 2015; status: completed.
02
Drugs
JLP-1207
03
Conditions
benign prostatic hyperplasia (BPH)overactive bladder (OAB)lower urinary tract symptoms (LUTS)
Beyond the preview
Go deeper on NCT02447367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02447367.